Literature DB >> 19116237

Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.

Dick C Chan1, P Hugh R Barrett, Esther M M Ooi, Juying Ji, Doris T Chan, Gerald F Watts.   

Abstract

CONTEXT: Hypercatabolism of high-density lipoprotein (HDL) apolipoprotein (apo) A-I results in low plasma apoA-I concentration. The mechanisms regulating apoA-I catabolism may relate to alterations in very low density lipoprotein (VLDL) metabolism and plasma adiponectin and serum amyloid A protein (SAA) concentrations.
OBJECTIVE: We examined the associations between the fractional catabolic rate (FCR) of HDL-apoA-I and VLDL kinetics, plasma adiponectin, and SAA concentrations. STUDY
DESIGN: The kinetics of HDL-apoA-I and VLDL-apoB were measured in 50 obese and 37 nonobese men using stable isotopic techniques.
RESULTS: In the obese group, HDL-apoA-I FCR was positively correlated with insulin, homeostasis model of assessment for insulin resistance (HOMA-IR) score, triglycerides, VLDL-apoB, and VLDL-apoB production rate (PR). In the nonobese group, HDL-apoA-I FCR was positively correlated with triglycerides, apoC-III, VLDL-apoB, and VLDL-apoB PR and negatively correlated with plasma adiponectin. Plasma SAA was not associated with HDL-apoA-I FCR in either group. In multiple regression analyses, VLDL-apoB PR and HOMA-IR score, and VLDL-apoB PR and adiponectin were independently predictive of HDL-apoA-I FCR in the obese and nonobese groups, respectively. HDL-apoA-I FCR was positively and strongly associated with HDL-apoA-I PR in both groups.
CONCLUSIONS: Variation in VLDL-apoB production, and hence plasma triglyceride concentrations, exerts a major effect on the catabolism of HDL-apoA-I. Insulin resistance and adiponectin may also contribute to the variation in HDL-apoA-I catabolism in obese and nonobese subjects, respectively. We also hypothesize that apoA-I PR determines a steady-state, lowered plasma of apoA-I, which may reflect a compensatory response to a primary defect in the catabolism of HDL-apoA-I due to altered VLDL metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116237     DOI: 10.1210/jc.2008-1457

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects.

Authors:  Faidon Magkos; Elisa Fabbrini; Bruce W Patterson; J Christopher Eagon; Samuel Klein
Journal:  Metabolism       Date:  2011-05-31       Impact factor: 8.694

2.  Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes.

Authors:  Susan Sam; Steven Haffner; Michael H Davidson; Ralph D'Agostino; Alfonso Perez; Theodore Mazzone
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

3.  Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.

Authors:  Ronald B Goldberg; Marinella Temprosa; Lisa Mele; Trevor Orchard; Kieren Mather; George Bray; Edward Horton; Abbas Kitabchi; Jonathan Krakoff; Santica Marcovina; Leigh Perreault; Neil White
Journal:  Metabolism       Date:  2015-12-02       Impact factor: 8.694

4.  Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome).

Authors:  Myriam Ensling; William Steinmann; Adam Whaley-Connell
Journal:  Cardiorenal Med       Date:  2011-01-17       Impact factor: 2.041

5.  HDL flux is higher in patients with nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen F Previs; Jaividhya Dasarathy; Kwangwon Lee; Abdullah Osme; Chunki Kim; Serguei Ilchenko; Shuhui W Lorkowski; Jonathan D Smith; Srinivasan Dasarathy; Takhar Kasumov
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-09-10       Impact factor: 4.310

6.  Epidemiologic evidence on serum adiponectin level and lipid profile.

Authors:  Vajihe Izadi; Elaheh Farabad; Leila Azadbakht
Journal:  Int J Prev Med       Date:  2013-02

7.  Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men.

Authors:  Lars P Sørensen; Esben Søndergaard; Birgitte Nellemann; Jens S Christiansen; Lars C Gormsen; Søren Nielsen
Journal:  Diabetes       Date:  2011-08-01       Impact factor: 9.461

8.  Insights into the molecular mechanisms of the anti-atherogenic actions of flavonoids in normal and obese mice.

Authors:  Elena V Shabrova; Olga Tarnopolsky; Ajay P Singh; Jorge Plutzky; Nicholi Vorsa; Loredana Quadro
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

9.  Unacylated Ghrelin is associated with the isolated low HDL-cholesterol obese phenotype independently of insulin resistance and CRP level.

Authors:  Juan-Patricio Nogueira; Marie Maraninchi; Sophie Béliard; Anne Marie Lorec; Bruno Berthet; Audrey Bégu-Le Corroller; Noémie Dubois; Rachel Grangeot; Catherine Mattei; Jean Gaudart; Alain Nicolay; Henri Portugal; Bernard Vialettes; René Valéro
Journal:  Nutr Metab (Lond)       Date:  2012-03-13       Impact factor: 4.169

10.  Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio.

Authors:  Gloria Lena Vega; Scott M Grundy
Journal:  J Obes       Date:  2013-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.